Oncology

Chronic fatigue, anxiety, and burnout are surging. A new wave of data-driven, integrative medicine claims to have the answer, moving beyond symptoms to the root cause.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

As federal support for science wanes, the National Cancer Center adds top minds from Stanford and Harvard to identify and fund the next wave of cancer cures.

A key update to a revolutionary cancer therapy reduces post-treatment restrictions, signaling a new era of patient-centric care and system efficiency in Canada.

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

A new alliance between Sun Life and Medzown moves beyond financial safety nets, using AI to steer patients to clinical trials and reshape corporate healthcare.

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

A new manufacturing patent for pelareorep de-risks Oncolytics' path to market, protecting the drug until 2044 and signaling commercial readiness.

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.